# Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

> **NCT04828174** · PHASE1 · SUSPENDED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 9 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Anaplastic Lymphoma
- Acute T Cell Leukemia
- T-lymphoblastic Lymphoma

## Interventions

- **DRUG:** anti-TRBC1 CAR-T cell therapy

## Key facts

- **NCT ID:** NCT04828174
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-03-31
- **Primary completion:** 2023-11-26
- **Final completion:** 2023-11-26
- **Target enrollment:** 9 (ESTIMATED)
- **Why stopped:** The trial was suspended due to the inability to enroll qualified participants
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04828174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04828174, "Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04828174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*